The9 Limited (Nasdaq: NCTY) announced that its Singapore investee Nanyang Biologics (NYB) has taken a critical step toward a Nasdaq listing after the U.S. Securities and Exchange Commission declared effective its Form F-4 registration statement. The announcement, issued via PRNewswire on August 11, 2026, details a business combination that values NYB at approximately $1.5 billion pre-transaction.
The SEC Greenlight and What Comes Next
With the SEC’s notice of effectiveness in hand, NYB now moves closer to a merger with a special purpose acquisition company (SPAC), a route that has drawn heightened regulatory attention in recent years. The effectiveness of the F-4 is not final approval but a key regulatory milestone, signaling the agency has no further comments on the filing. The combination now hinges on the SPAC’s extraordinary general meeting set for August 19, 2026, and Nasdaq’s final listing approval. NYB, which plans to trade under the ticker “NYB,” focuses on AI-driven drug discovery using natural compounds, powered by its Vecura™ AI platform and a deep library of over one million natural compounds.
Implications for The9’s Diversified Tech Portfolio
The9, known for its pivot from online gaming into high-tech ventures including blockchain infrastructure and cryptocurrency mining, stands to benefit materially from NYB’s public debut. Through its wholly-owned subsidiary Gamenow.net (Hong Kong) Limited, The9 expects to hold 15–16% of the combined company post-closing. This stake provides exposure to a burgeoning AI-biotech sector, complementing The9’s existing digital asset operations. While the company’s primary revenue drivers have included Bitcoin mining and cloud services, the NYB listing could add a significant liquid asset to its balance sheet, potentially enhancing The9’s own valuation in the public markets.
For investors in The9—listed on Nasdaq as NCTY—the NYB milestone may serve as a partial validator of the company’s strategy to incubate and invest in adjacent technology verticals. As the crypto market continues to face regulatory scrutiny globally, The9’s diversified holdings could offer a counterbalance to sector-specific volatility.
